<DOC>
	<DOCNO>NCT01986491</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( medication body ) , dose-proportionality , safety tolerability JNJ 39393406 follow single dose oral administration two solid oral formulation Part 1 ; base profile Part 1 , one formulation assess select investigate pharmacokinetics fast condition Part 2 repeat dose Part 3 .</brief_summary>
	<brief_title>A Study Solid Formulations JNJ-39393406 Healthy Male Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) single center study conduct 3 part ( Part 1 , Part 2 , Part 3 ) . The study consist 3 phase include , screen phase , treatment phase , follow-up phase . Part 1 four-way cross-over ( method use switch participant one treatment arm another clinical study ) study compare pharmacokinetics , dose-proportionality , safety tolerability JNJ 39393406 follow single dose oral administration two solid oral formulation ( X Y ) . Approximately 12 participant enrol Part 1 . Part 2 two-way cross-over study separate group participant ass pharmacokinetics fast condition relative bioavailability ( extent medication substance become available body ) select solid formulation Part 1 compare solution formulation . Approximately 8 participant enrol Part 2 . In Part 3 , single repeat dose pharmacokinetics administration select formulation Part 1 assess 7 consecutive day . The participant participate Parts 2 3 study . Safety evaluate assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination , neurological examination . The duration participation study individual participant approximately 8 week ( include screen follow visit ) .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Healthy male participant Body mass index ( BMI ) 18 30 kg/m2 ( BMI calculate weight [ kilogram ] divide square height [ meter ] ) Willing adhere prohibition restriction specify protocol Must sign informed consent document indicate understand purpose procedure require study willing participate study Clinically significant abnormal value clinical chemistry , hematology urinalysis screen admission Clinically significant abnormal physical examination , neurological examination , vital sign 12 lead electrocardiogram screen Significant history current significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematological disease , bronchospastic respiratory disease , dyspnea , diabetes mellitus , renal hepatic insufficiency , thyroid disease , infection , illness investigator considers clinically significant Significant history current psychiatric neurological illness Serology positive hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus antibody screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-39393406</keyword>
	<keyword>Relative Bioavailability</keyword>
	<keyword>Solid Formulation</keyword>
</DOC>